Vitreoretinal Lymphoma: Staging and Treatment

摘要: Staging and treatment of primary vitreoretinal lymphoma (PVRL) are based upon the understanding that PVRL is a variant central nervous system (PCNSL). Approximately 56–85 % individuals initially diagnosed with will subsequently develop (CNS) involvement over period many months to several years. Conversely, about 25 patients PCNSL have detectable intraocular at time diagnosis. There general consensus regimens containing high-dose methotrexate, or without whole-brain radiation therapy (WBRT), yield better response rates outcomes than do not contain methotrexate. Disease relapse in CNS major issue, particularly after local ocular radiotherapy intravitreal chemotherapy. Management should be undertaken by multidisciplinary team experts fields ophthalmic oncology, pathology, neuro-oncology for optimal planning continued patient surveillance.